STAAR Surgical Company (STAA): Price and Financial Metrics

STAAR Surgical Company (STAA)

Today's Latest Price: $72.42 USD

1.15 (1.61%)

Updated Dec 1 6:55pm

Add STAA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

STAA Stock Summary

  • STAA's current price/earnings ratio is 372.48, which is higher than 97.8% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for STAA is currently 298.31, higher than 98.75% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 21.36, Staar Surgical Co has a higher such ratio than 91.86% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Staar Surgical Co are AOSL, GLUU, VICR, PCTY, and CALX.
  • Visit STAA's SEC page to see the company's official filings. To visit the company's web site, go to

STAA Stock Price Chart Interactive Chart >

Price chart for STAA

STAA Price/Volume Stats

Current price $72.42 52-week high $85.63
Prev. close $71.27 52-week low $23.20
Day low $70.38 Volume 591,100
Day high $72.76 Avg. volume 559,274
50-day MA $68.55 Dividend yield N/A
200-day MA $49.79 Market Cap 3.34B

STAAR Surgical Company (STAA) Company Bio

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company was founded in 1982 and is based in Monrovia, California.

STAA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$72.42$0.99 -99%

Below please find a table outlining a discounted cash flow forecast for STAA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Staar Surgical Co ranked in the 3th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Staar Surgical Co, consider:

  • Staar Surgical Co's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -32.59. This coverage rate is greater than that of just 4.14% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • As a business, Staar Surgical Co experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

CTLT, AGHC, ALC, AMRN, and ATRS can be thought of as valuation peers to STAA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

STAA Latest News Stream

Event/Time News Detail
Loading, please wait...

STAA Latest Social Stream

Loading social stream, please wait...

View Full STAA Social Stream

Latest STAA News From Around the Web

Below are the latest news stories about Staar Surgical Co that investors may wish to consider to help them evaluate STAA as an investment opportunity.

STAAR Surgical (STAA) Investor Presentation - Slideshow

The following slide deck was published by STAAR Surgical Company in conjunction with this event....

SA Transcripts on Seeking Alpha | September 24, 2020

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against STAAR Surgical Company (STAA)

LOS ANGELES, Sept. 15, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz reminds investors of the upcoming October 19, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased STAAR Surgical Company ("STAAR" or the "Company")…

PR Newswire | September 15, 2020

STAA SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Staar Surgical Company

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the common stock of Staar Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) between February 26, 2020, and August 10, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the Central District of Ca

Business Wire | September 15, 2020

STAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that patient enrollment for the primary study analysis cohort of 300 subjects has been achieved in its U.S. FDA clinical trial, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian® Implantable Collamer® Lens.” Primary study analysis will be conducted when 300 primary eyes complete 6

Business Wire | September 14, 2020

ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds STAAR Surgical Company Investors of Important October 19 Deadline in Securities Class Action – STAA

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of STAAR Surgical Company (NASDAQ: STAA) between February 26, 2020 and August 10, 2020, inclusive (the “Class Period”) of the important October 19, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for STAAR investors under the federal securities laws. To join the STAAR class action, go to

Business Wire | September 14, 2020

Read More 'STAA' Stories Here

STAA Price Returns

1-mo 0.93%
3-mo 39.06%
6-mo 67.72%
1-year 96.69%
3-year 327.26%
5-year 784.25%
YTD 105.91%
2019 10.22%
2018 105.87%
2017 42.86%
2016 51.96%
2015 -21.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9005 seconds.